^
Association details:
| Biomarker: | DNMT3A mutation |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
BCR-ABL1 p190 in CML: A Minor Breakpoint with a Major Impact
Published date:
11/06/2019
Excerpt:
CML patients with p190 had a median age of 72.5 years at the diagnosis (range: 50-80) and all received imatinib as a frontline treatment. Only one patient achieved a fluctuating major molecular response (MMR) by 12 months while the rest of the patients showed primary resistance to treatment...By exome sequencing we identified 26 variants in p190-CML samples (median per patient=7, range: 2-10), including variants in ASXL1, DNMT3A and KDM4D genes.
DOI:
https://doi.org/10.1182/blood-2019-126584
